Health and FitnessHealth and Fitness
Thu, June 14, 2012
[ Thu, Jun 14th 2012 ] - Market Wire
BMO Survey
[ Thu, Jun 14th 2012 ] - Market Wire
FALL OF CYBERTRON
[ Thu, Jun 14th 2012 ] - Market Wire
Mortgage Rates Move Slightly
[ Thu, Jun 14th 2012 ] - Market Wire
Bannerman Board Changes

InterMune to Present At The Wells Fargo Securities Healthcare Conference


Published on 2012-06-14 04:10:39 - Market Wire
  Print publication without navigation


InterMune to Present At The Wells Fargo Securities Healthcare Conference -- BRISBANE, Calif., June 14, 2012 /PRNewswire/ --

InterMune to Present At The Wells Fargo Securities Healthcare Conference

[ ]

BRISBANE, Calif., June 14, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: [ ITMN ]) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Wells Fargo Securities 2012 Healthcare Conference in Boston on Tuesday, June 19 at 3:00 p.m. EDT

To access a live audio webcast of any of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at [ www.intermune.com ]. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit [ www.intermune.com ].

SOURCE InterMune, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.intermune.com ]